A phase I/II clinical trial of preoperative docetaxel/oxaliplatin/S-1 (DOS) combination therapy for esophagogastric junction adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

if the site is at the level of the esophagogastric junction, a laparotomy is preferable, and the stomach can be used to reinforce the repair. If the damage to the esophagus is too extensive to ...

Choose from Esophageal Ulcer stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and ...

Gastro Esophageal Junction Neuroendocrine Tumor Market Outlook 2025-2035: The gastro esophageal junction neuroendocrine tumor market size reached a value of USD 1,120.2 Million in 2024. Looking ...

gastric cancer, gastroesophageal junction carcinomas, non-small cell lung cancer, metastatic urothelial carcinoma, esophageal squamous cell carcinoma, squamous and adenocarcinoma of non-small cell ...

Sabestomig (AZD-7789) is under development for the treatment of crohn''s disease, solid tumors including squamous and non squamous non-small cell lung carcinoma, gastric and gastroesophageal junction ...

11 Patients with a tumor in the esophagus or a tumor with an epicenter within 5 cm of the esophagogastric junction and extension ... When possible, the luminal location of the tumor before therapy ...

A combination of camrelizumab with nab-paclitaxel (Abraxane), oxaliplatin, and fluorouracil (Nab-POF) resulted in safe conversion rates and high efficacy responses at 3 years in patients with gastric ...

Effect of SHR-1701 on chemotherapy (chemo)-induced myelosuppression: Data from a phase 3 study in HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA). This is an ASCO Meeting ...